

# Pierre Fenaux

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2618697/pierre-fenaux-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

226  
papers

24,089  
citations

58  
h-index

154  
g-index

236  
ext. papers

28,902  
ext. citations

5.2  
avg, IF

6.15  
L-index

#	Paper	IF	Citations
226	International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. <i>Blood</i> , <b>1997</b> , 89, 2079-2088	2.2	3508
225	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , <b>2017</b> , 129, 424-447	2.2	2764
224	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , <b>2010</b> , 115, 453-74	2.2	2483
223	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 223-32	21.7	1961
222	Revised international prognostic scoring system for myelodysplastic syndromes. <i>Blood</i> , <b>2012</b> , 120, 2454-65		1799
221	Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 562-9	2.2	756
220	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , <b>2009</b> , 113, 1875-91	2.2	720
219	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , <b>2013</b> , 122, 2943-64	2.2	437
218	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. <i>Cancer</i> , <b>2008</b> , 113, 1351-61	6.4	386
217	Prognostic score including gene mutations in chronic myelomonocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2428-36	2.2	373
216	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. <i>Blood</i> , <b>2011</b> , 118, 3765-76	2.2	348
215	Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3322-7	2.2	339
214	Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. <i>Blood</i> , <b>2011</b> , 117, 403-11	2.2	297
213	Myelodysplastic syndromes. <i>Lancet, The</i> , <b>2014</b> , 383, 2239-52	40	264
212	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. <i>Blood</i> , <b>2008</b> , 111, 574-82	2.2	243
211	DNA topoisomerase II in therapy-related acute promyelocytic leukemia. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 1529-38	59.2	229
210	Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2662-70	2.2	203

209	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , <b>2017</b> , 129, 1753-1762	2.2	189
208	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. <i>Blood</i> , <b>2010</b> , 115, 1690-6	2.2	186
207	Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. <i>Blood</i> , <b>2004</b> , 104, 321-7	2.2	176
206	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. <i>Blood</i> , <b>2011</b> , 118, 3824-31	2.2	166
205	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 140-151	59.2	160
204	Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 437-44	2.2	154
203	Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). <i>Leukemia Research</i> , <b>2010</b> , 34, 864-70	2.7	150
202	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2988-96	2.2	147
201	Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5703-10	2.2	142
200	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. <i>Nature Communications</i> , <b>2016</b> , 7, 10767	17.4	140
199	Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. <i>Cancer</i> , <b>2011</b> , 117, 2697-702	6.4	139
198	Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. <i>Blood</i> , <b>2007</b> , 109, 5129-35	2.2	138
197	Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. <i>Blood</i> , <b>2008</b> , 111, 1078-84	2.2	135
196	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. <i>Blood</i> , <b>2009</b> , 113, 3947-52	2.2	133
195	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , <b>2020</b> , 26, 1549-1556	50.5	118
194	Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 292-300	2.2	115
193	Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. <i>Leukemia Research</i> , <b>2014</b> , 38, 751-5	2.7	112
192	17p Deletion in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Analysis of Breakpoints and Deleted Segments by Fluorescence In Situ. <i>Blood</i> , <b>1998</b> , 91, 1008-1015	2.2	108

191	Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. <i>Cancer</i> , <b>2014</b> , 120, 1838-46	6.4	107
190	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. <i>Rheumatology</i> , <b>2016</b> , 55, 291-300	3.9	103
189	How we treat lower-risk myelodysplastic syndromes. <i>Blood</i> , <b>2013</b> , 121, 4280-6	2.2	101
188	A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. <i>Haematologica</i> , <b>2013</b> , 98, 1067-72	6.6	99
187	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. <i>Lancet Haematology</i> , <b>2017</b> , 4, e127-e136	14.6	95
186	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). <i>Haematologica</i> , <b>2014</b> , 99, 1041-9	6.6	95
185	Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. <i>European Journal of Haematology</i> , <b>2010</b> , 85, 130-8	3.8	95
184	Time-dependent changes in mortality and transformation risk in MDS. <i>Blood</i> , <b>2016</b> , 128, 902-10	2.2	93
183	Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1584-1594	2.2	89
182	Mutations of the P53 gene in acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>1992</b> , 80, 178-83	4.5	88
181	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , <b>2019</b> , 33, 1747-1758	10.7	88
180	An International MDS/MPN Working Group perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , <b>2015</b> , 100, 1117-30	6.6	79
179	Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 410-6	7.1	78
178	Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2668-76	2.2	78
177	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. <i>Lancet Haematology</i> , <b>2018</b> , 5, e63-e72	14.6	76
176	Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 244-9	4.5	65
175	Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. <i>Annals of Hematology</i> , <b>2008</b> , 87, 345-52	3	64
174	Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Leukemia Research</i> , <b>2016</b> , 43, 13-7	2.7	63

173	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , <b>2018</b> , 2, 1765-1772	7.8	63
172	Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. <i>British Journal of Haematology</i> , <b>1997</b> , 98, 983-91	4.5	61
171	Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. <i>British Journal of Haematology</i> , <b>2001</b> , 112, 927-35	4.5	61
170	Infections in myelodysplastic syndromes. <i>Haematologica</i> , <b>2012</b> , 97, 1459-70	6.6	59
169	A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin- $\alpha$ in anemic patients with low-risk MDS. <i>Leukemia</i> , <b>2018</b> , 32, 2648-2658	10.7	58
168	Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. <i>Cancer</i> , <b>2011</b> , 117, 992-1000	6.4	58
167	Germline DDX41 mutations define a significant entity within adult MDS/AML patients. <i>Blood</i> , <b>2019</b> , 134, 1441-1444	2.2	57
166	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1591-1597	2.2	55
165	Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. <i>Genes Chromosomes and Cancer</i> , <b>2012</b> , 51, 1086-92	5	54
164	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 472-5	1.9	54
163	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. <i>Blood</i> , <b>2013</b> , 122, 2286-8	2.2	54
162	Eprenetapopt Plus Azacitidine in -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM). <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1575-1583	2.2	54
161	Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. <i>Lancet Haematology</i> , <b>2018</b> , 5, e117-e126	14.6	52
160	Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. <i>Seminars in Hematology</i> , <b>2004</b> , 41, 6-12	4	51
159	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. <i>EBioMedicine</i> , <b>2018</b> , 31, 174-181	8.8	49
158	BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. <i>Cancer Research</i> , <b>2007</b> , 67, 11657-67	10.1	49
157	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. <i>HemaSphere</i> , <b>2018</b> , 2, e150	0.3	48
156	Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 372-83	4.5	47

155	The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. <i>Blood</i> , <b>2012</b> , 120, 5084-5	2.2	46
154	Synergistic effects of PRIMA-1 (APR-246) and 5-azacitidine in -mutated myelodysplastic syndromes and acute myeloid leukemia. <i>Haematologica</i> , <b>2020</b> , 105, 1539-1551	6.6	45
153	Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. <i>British Journal of Haematology</i> , <b>1996</b> , 94, 116-9	4.5	41
152	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , <b>2020</b> , 7, e601-e612	14.6	41
151	Review of azacitidine trials in Intermediate-2 and High-risk myelodysplastic syndromes. <i>Leukemia Research</i> , <b>2009</b> , 33 Suppl 2, S7-11	2.7	40
150	A randomized phase II trial of azacitidine +/- epoetin- $\alpha$ in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. <i>Haematologica</i> , <b>2016</b> , 101, 918-25	6.6	40
149	High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, L17-23	5.7	39
148	Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Soci� Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1349-55	4.7	39
147	Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. <i>Leukemia Research</i> , <b>2015</b> , 39, 501-4	2.7	38
146	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 2466-2480	10.7	37
145	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. <i>Leukemia</i> , <b>2018</b> , 32, 1380-1392	10.7	37
144	BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. <i>Blood</i> , <b>2013</b> , 122, 2864-76	2.2	36
143	Valuation of transfusion-free living in MDS: results of health utility interviews with patients. <i>Health and Quality of Life Outcomes</i> , <b>2009</b> , 7, 81	3	36
142	Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2018</b> , 132, 3091-3091	2.2	36
141	Autoimmune manifestations associated with myelodysplastic syndromes. <i>Annals of Hematology</i> , <b>2018</b> , 97, 2015-2023	3	35
140	Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. <i>Cell Cycle</i> , <b>2011</b> , 10, 2323-30	4.7	35
139	Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. <i>Haematologica</i> , <b>2012</b> , 97, 213-8	6.6	35
138	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. <i>Blood</i> , <b>2016</b> , 127, 749-60	2.2	34

137	Molecular remission as a therapeutic objective in acute promyelocytic leukemia. <i>Leukemia</i> , <b>2018</b> , 32, 1671-1678	10.7	34
136	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. <i>Leukemia Research</i> , <b>2011</b> , 35, 863-7	2.7	34
135	Azacitidine in adult patients with acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 116, 159-177	7	31
134	Impact of iron overload in myelodysplastic syndromes. <i>Blood Reviews</i> , <b>2009</b> , 23 Suppl 1, S15-9	11.1	31
133	Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. <i>Annals of Hematology</i> , <b>2014</b> , 93, 1-11	3	30
132	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. <i>Blood</i> , <b>2018</b> , 132, 1-11	2.2	29
131	Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 906-913	4.5	28
130	Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 730-47	4.5	28
129	Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. <i>Leukemia Research</i> , <b>2013</b> , 37, 259-65	2.7	28
128	How we manage adults with myelodysplastic syndrome. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 1016-1927	4.9	28
127	Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?. <i>Haematologica</i> , <b>2016</b> , 101, e280-3	6.6	28
126	A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. <i>Haematologica</i> , <b>2019</b> , 104, 1565-1571	6.6	26
125	A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. <i>Leukemia</i> , <b>2018</b> , 32, 1493-1499	10.7	25
124	Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. <i>Best Practice and Research in Clinical Haematology</i> , <b>2013</b> , 26, 355-64	4.2	25
123	Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 556-9	7.1	25
122	de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases. <i>Leukemia Research</i> , <b>1990</b> , 14, 1053-9	2.7	25
121	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1223-1233	2.2	25
120	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 48-56	2.2	24

119	Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. <i>European Journal of Haematology</i> , <b>2014</b> , 93, 429-38	3.8	23
118	Promyelocytic blast crisis of Philadelphia-positive thrombocythemia with translocations (9;22) and (15;17). <i>Cancer Genetics and Cytogenetics</i> , <b>1987</b> , 29, 311-4		23
117	Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. <i>Nature Communications</i> , <b>2018</b> , 9, 2047	17.4	23
116	Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , <b>2017</b> , 52, 50-57	2.7	22
115	Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 134-160	4.5	22
114	Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. <i>Haematologica</i> , <b>2018</b> , 103, 2033-2039	6.6	19
113	Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the. <i>Haematologica</i> , <b>2017</b> , 102, 728-735	6.6	17
112	An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3025-3034	12.9	17
111	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1426-1436	2.2	17
110	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	16
109	Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 859-63	7.1	15
108	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. <i>Leukemia Research</i> , <b>2014</b> , 38, 29-33 <sup>2-7</sup>		15
107	Treatment of older adults with acute promyelocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , <b>2003</b> , 16, 495-501	4.2	14
106	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. <i>Leukemia</i> , <b>2020</b> , 34, 2333-2341	10.7	13
105	BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. <i>Oncotarget</i> , <b>2017</b> , 8, 47103-47109	3.3	13
104	Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 63-69	3.8	13
103	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1113-1120	1.9	12
102	Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. <i>Cancer</i> , <b>2015</b> , 121, 2393-9	6.4	11



101	The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, 136-144.e7	2	11
100	Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 81926-81935	3.3	11
99	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102446	13.6	11
98	Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 975-979	4.5	11
97	Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. <i>Leukemia Research</i> , <b>2017</b> , 63, 72-77	2.7	10
96	Development of luspatercept to treat ineffective erythropoiesis. <i>Blood Advances</i> , <b>2021</b> , 5, 1565-1575	7.8	10
95	UBA1 Variations in Neutrophilic Dermatitis Skin Lesions of Patients With VEXAS Syndrome. <i>JAMA Dermatology</i> , <b>2021</b> , 157, 1349-1354	5.1	10
94	Question prompt list responds to information needs of myelodysplastic syndromes patients and caregivers. <i>Leukemia Research</i> , <b>2015</b> , 39, 599-605	2.7	9
93	Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. <i>Leukemia</i> , <b>2021</b> , 35, 2720-2724	10.7	9
92	GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 5	22.4	8
91	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 37866-37874	3.3	8
90	Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 350-359	4.5	7
89	Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myelodysplasies. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 843-850	4.5	7
88	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. <i>Blood</i> , <b>2016</b> , 128, 121-121	2.2	7
87	Outcome Of Patients With IPSS Intermediate (int) Or High Risk Myelodysplastic Syndrome (MDS) According To Donor Availability: A Multicenter Prospective Non Interventional Study For The SFGM-TC and GFM. <i>Blood</i> , <b>2013</b> , 122, 301-301	2.2	7
86	Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	7
85	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 879-884	5.3	7
84	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. <i>Haematologica</i> , <b>2019</b> , 104, 497-504	6.6	7

83	Association between health literacy, communication and psychological distress among myelodysplastic syndromes patients. <i>Leukemia Research</i> , <b>2018</b> , 73, 44-50	2.7	7
82	Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2594-2596	1.9	5
81	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. <i>Leukemia Research</i> , <b>2014</b> , 38, 258-62	2.7	5
80	High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM).. <i>Blood</i> , <b>2004</b> , 104, 68-68	2.2	5
79	Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). <i>Blood</i> , <b>2011</b> , 118, 609-609	2.2	5
78	Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , <b>2012</b> , 120, 3830-3830	2.2	5
77	Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q. <i>Blood</i> , <b>2012</b> , 120, 3833-3833	2.2	5
76	Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease. <i>Leukemia</i> , <b>2021</b> , 35, 2731-2733	10.7	5
75	Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. <i>Leukemia Research</i> , <b>2013</b> , 37, 312-9	2.7	4
74	Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 131	22.4	4
73	Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study. <i>Blood</i> , <b>2020</b> , 136, 10-12	2.2	4
72	Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients. <i>Blood</i> , <b>2013</b> , 122, 389-389	2.2	4
71	DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies. <i>Oncotarget</i> , <b>2015</b> , 6, 32494-508	3.3	4
70	Guadecitabine in myelodysplastic syndromes: promising but there is still progress to be made. <i>Lancet Haematology</i> , <b>2019</b> , 6, e290-e291	14.6	3
69	Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 405-417	4.5	3
68	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. <i>Leukemia</i> , <b>2018</b> , 32, 2066-2069	10.7	3
67	Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/-Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone. <i>Blood</i> , <b>2010</b> , 116, 1880-1880	2.2	3
66	Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study. <i>Blood</i> , <b>2019</b> , 123, 1553-1553	2.2	3

65	Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group. <i>Blood</i> , <b>2015</b> , 126, 451-451	2.2	3
64	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. <i>Haematologica</i> , <b>2020</b> , 105, 2516-2523	6.6	3
63	Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1475-1483	1.9	3
62	Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
61	Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 461-464	4.5	2
60	Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes. <i>Leukemia Research</i> , <b>2015</b> ,	2.7	2
59	Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine. <i>Blood</i> , <b>2012</b> , 120, 1706-1706	2.2	2
58	Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).. <i>Blood</i> , <b>2012</b> , 120, 2801-2801	2.2	2
57	Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry. <i>Blood</i> , <b>2012</b> , 120, 700-700	2.2	2
56	A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients. <i>Blood</i> , <b>2013</b> , 122, 1513-1513	2.2	2
55	Time Changes In Predictive Power Of MDS Prognostic Scores [Effects On Revised Scores Such As The IPSS-R, Impact Of Age. <i>Blood</i> , <b>2013</b> , 122, 1544-1544	2.2	2
54	Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , <b>2013</b> , 122, 2770-2770	2.2	2
53	Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q). <i>Blood</i> , <b>2013</b> , 122, 390-390	2.2	2
52	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score. <i>Blood</i> , <b>2015</b> , 126, 2554-2554	2.2	2
51	USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still@ Disease in Elderly Patients. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
50	Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?. <i>Leukemia</i> , <b>2020</b> , 34, 2552-2560	10.7	2
49	Guideline-based indicators for adult patients with myelodysplastic syndromes. <i>Blood Advances</i> , <b>2020</b> , 4, 4029-4044	7.8	2
48	Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 336-343	4.5	2

47	A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM). <i>Haematologica</i> , <b>2019</b> , 104, e131-e133	6.6	2
46	Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Haematologica</i> , <b>2021</b> , 106, 1414-1422	6.6	2
45	Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial). <i>Haematologica</i> , <b>2018</b> , 103, e519-e521	6.6	2
44	BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
43	Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide. <i>British Journal of Haematology</i> , <b>2020</b> , 189, e133-e137	4.5	1
42	Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 304-308	4.5	1
41	Awareness of acute myeloid leukaemia risk induced by diagnosis of a myelodysplastic syndrome. <i>Leukemia Research</i> , <b>2016</b> , 46, 79-84	2.7	1
40	Impact of Cytogenetics and Cytogenetic Response On Outcome in MDS Treated with Azacitidine (AZA).. <i>Blood</i> , <b>2012</b> , 120, 2807-2807	2.2	1
39	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM).. <i>Blood</i> , <b>2012</b> , 120, 2814-2814	2.2	1
38	Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML). <i>Blood</i> , <b>2012</b> , 120, 3811-3811	2.2	1
37	Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure. <i>Blood</i> , <b>2012</b> , 120, 3825-3825	2.2	1
36	Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. <i>Blood</i> , <b>2012</b> , 120, 422-422	2.2	1
35	BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients. <i>Blood</i> , <b>2012</b> , 120, 701-701	2.2	1
34	Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts). <i>Blood</i> , <b>2012</b> , 120, 890-890	2.2	1
33	Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE). <i>Blood</i> , <b>2013</b> , 122, 1406-1406	2.2	1
32	Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities. <i>Blood</i> , <b>2013</b> , 122, 1512-1512	2.2	1
31	Tracking the Extramedullary PML-RAR $\beta$ Positive Cell Reservoirs in a Preclinical Model of APL: Biomarker of Long-Term Drug Efficacy. <i>Blood</i> , <b>2012</b> , 120, 1510-1510	2.2	1
30	Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS [Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies. <i>Blood</i> , <b>2012</b> , 120, 1720-1720	2.2	1

29	A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q [A Study By The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , <b>2013</b> , 122, 2750-2750	2.2	1
28	Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes. <i>Hemato</i> , <b>2021</b> , 2, 329-346		1
27	IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS7056-TPS7056	2.2	1
26	A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. <i>Leukemia Research</i> , <b>2021</b> , 104, 106555	2.7	1
25	Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman. <i>Case Reports in Hematology</i> , <b>2020</b> , 2020, 3686584	0.7	1
24	Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study. <i>Blood</i> , <b>2012</b> , 120, 3808-3808	2.2	0
23	Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data. <i>Journal of Molecular Diagnostics</i> , <b>2021</b> , 23, 347-357	5.1	0
22	Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned. <i>Blood Reviews</i> , <b>2021</b> , 50, 100851	11.1	0
21	In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , <b>2021</b> , 194, e77-e79	4.5	0
20	Treatment with Hypomethylating Agents (HMA). <i>Hematologic Malignancies</i> , <b>2018</b> , 131-139	0	
19	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 246-249	1.9	
18	Myelodysplastic Syndrome and Giant Cell Arteritis: A Nonfortuitous Association that Geriatricians Should Know About. <i>Journal of the American Geriatrics Society</i> , <b>2017</b> , 65, 2335-2337	5.6	
17	Mutations in the Exon 12 of the JAK2 Gene Appeared To Be a Rare Event Essentially Clustered in V617F JAK2 Negative PV Patients.. <i>Blood</i> , <b>2007</b> , 110, 2534-2534	2.2	
16	Treatment Algorithms for Lower-Risk Myelodysplastic Syndrome <b>2020</b> , 131-145		
15	Prognostic Factors of Infections and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA): A Prospective Study. <i>Blood</i> , <b>2014</b> , 124, 1917-1917	2.2	
14	Therapeutic Strategies in Patients with Atypical CML (aCML) and Unclassified MDS/MPN (MDS/MPN-U). a Single Center Report. <i>Blood</i> , <b>2014</b> , 124, 5610-5610	2.2	
13	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloblastic Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Patients (pts) Older Than 50 Years: a Retrospective Single Center Study. <i>Blood</i> , <b>2008</b> , 112, 3309-3309	2.2	
12	Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA). <i>Blood</i> , <b>2011</b> , 118, 5028-5028	2.2	

- 11 Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn 7)? Results of a Retrospective Study From the GFM and GESMD Registries. *Blood*, **2012**, 120, 1713-1713
- 10 Equivalent Outcome Between Reduced Intensity Versus Conventional Myeloablative Conditioning Hematopoietic Stem Cell Transplantation for Patients Older Than 35 Years with Acute Myeloid Leukemia.. *Blood*, **2012**, 120, 3103-3103 2.2
- 9 Prognostic Factors of Severe Infections, and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA). A Single Center Study On 144 Patients. *Blood*, **2012**, 120, 3812-3812
- 8 Lithium Treatment Potentiates Both in Vitro and in Vivo Retinoic Acid Efficacy in APL.. *Blood*, **2012**, 120, 2614-2614 2.2
- 7 Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML). *Blood*, **2012**, 120, 309-309 2.2
- 6 Effector CD4<sup>+</sup>CD45RA<sup>int</sup>CD25<sup>bright</sup>Foxp3<sup>bright</sup> Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status.. *Blood*, **2012**, 120, 2808-2808 2.2
- 5 NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS). *Blood*, **2012**, 120, 3835-3835 2.2
- 4 Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL—Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. *Blood*, **2013**, 122, 495-495 2.2
- 3 The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism. *Blood*, **2013**, 122, 2761-2761 2.2
- 2 Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing. *Blood*, **2013**, 122, 740-740 2.2
- 1 Exome analysis of treatment-related AML after APL suggests secondary evolution. *British Journal of Haematology*, **2019**, 185, 984-987 4.5